.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AH02_Everolimus.Everolimus

Information

Everolimus is an orally available mTOR inhibitor used for the treatment of various cancers (including renal cell carcinoma, breast cancer, and neuroendocrine tumors) and for prevention of organ rejection after transplantation. It is currently approved by regulatory authorities for such uses.

Pharmacokinetics

Population pharmacokinetic model in adult solid organ transplant recipients (kidney transplant), both male and female, after oral administration.

References

1. Combes, FP, et al., & Nedelman, J (2018). Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex. Journal of pharmacokinetics and pharmacodynamics 45(5) 707–719. DOI:10.1007/s10928-018-9600-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29992479

2. Tanaka, A, et al., & Matsubara, K (2016). Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. Therapeutic drug monitoring 38(6) 663–669. DOI:10.1097/FTD.0000000000000344 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27661398

3. Moes, DJ, et al., & Guchelaar, HJ (2012). Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clinical pharmacokinetics 51(7) 467–480. DOI:10.2165/11599710-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22624503

Revisions

• 06/2025 initial generated model